New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
05:43 EDTPSTIPluristem Therapeutics submits FDA orphan drug application for PLX-PAD
Pluristem Therapeutics announced it is submitting its application to the FDA requesting the company to be granted Orphan Drug Designation for its PLacental eXpanded, or PLX-PAD, cells in the treatment of severe preeclampsia. Pluristem has successfully received Orphan Drug Designation from the FDA for its PLX cells in two other indications: the treatment of aplastic anemia; and the treatment of Buerger's disease.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
09:52 EDTPSTIPluristem raises $17M in a registered direct offering
Subscribe for More Information
June 24, 2015
05:30 EDTPSTIPluristem granted Australian patent for 3D cell expansion technology
Pluristem Therapeutics announced that it has been granted an Australian patent titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy". Patent #2009288781 covers Pluristem's proprietary, three-dimensional method of growing cells from placental or adipose tissue, cells produced by the process, and the use of such cells in the potential treatment of a broad range of conditions. These include peripheral artery disease, other ischemic and cardiovascular diseases, graft-versus-host disease, organ transplantation, cancer, and autoimmune diseases. The patent term will extend until 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use